In the randomized SHOCK-COOL trial, the prognostic role of Gal-3 was investigated in 40 patients with cardiogenic shock complicating acute myocardial infarction, who were randomly assigned to the mild therapeutic hypothermia 33 °C or control groups. The gene discussed is LGALS3; the disease is myocardial infarction.